We have opened a Phase I clinical trial (NCT01044069) to evaluate the safety of autologous, CD19-targeted T cells as a supplement to cytotoxic chemotherapy for adults with B-ALL [5]. Here, CD19 is linked to acute lymphoblastic leukemia.